Thrombotic microangiopathy associated with proteasome inhibitors

Ahad Lodhi, Abhishek Kumar, Muhammad U. Saqlain, and Manish Suneja

Department of Nephrology, Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52246, USA

Correspondence to: Ahad Lodhi; E-mail: ahadaftab@gmail.com

Abstract

The ubiquitin proteasome pathway plays a key role in cell cycle, function and survival. Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome pathway, indicated in treatment of patients with multiple myeloma. In the past few years, there have been few case reports that have highlighted the association between proteasome inhibitors (BTZ and CFZ) with acute kidney injury (AKI). In most of these case reports and initial trials, the underlying mechanism of AKI has been unclear. In this article, we discuss the association and pathogenesis of proteasome inhibitors-associated AKI. We also report the first case of CFZ-associated AKI with kidney biopsy evidence of thrombotic microangiopathy and the presence of microangiopathic hemolytic anemia.

Key words: onconephrology

Proteasome inhibitors

The ubiquitin proteasome pathway plays a key role in the targeted destruction of cellular proteins and is central for cell cycle, function and survival, making proteasome inhibition an attractive target in cancer [1–4]. Bortezomib (BTZ), the first inhibitor of the proteasome pathway, was approved in 2003 for the treatment of multiple myeloma (MM) [5, 6]. It was initially approved only for MM post-transplant relapse or as a second-line treatment in patients unsuitable for transplantation. In 2008, it was approved for induction therapy in MM. It is a boron molecule that reversibly inhibits threonine residue of 26S proteasome. Carfilzomib (CFZ) is a second generation proteasome inhibitor that was approved in 2012 for patients with MM who had relapsed and were refractory to BTZ and at least one thalidomide derivative [7–9]. CFZ inhibits the beta-5 proteasome subunit by forming an irreversible adduct through two covalent bonds, allowing more sustained and more specific inhibition than the single reversible adduct formed by BTZ [10]. Unlike BTZ, CFZ is not associated with peripheral neuropathy but has a higher incidence of cardiopulmonary and kidney toxicity. BTZ not only inhibits beta-5 proteasome but also some neuroprotective molecules and serine proteases that are involved in kidney injury, which explains the higher incidence of peripheral neuropathy but lower incidence of kidney dysfunction compared with CFZ [11].

Proteasome inhibitors and acute kidney injury

BTZ’s approval for initial treatment of MM was based on the Phase 2 trials CREST and SUMMIT [6, 12, 13]. In these early trials, acute kidney injury (AKI) or thrombotic microangiopathy (TMA) was not reported as a drug-related adverse event [14]. CFZ’s initial approval for the treatment of MM was largely based on a Phase 2 trial by Siegel et al. [15, 16]. In this study, an increase in serum creatinine (sCr) was reported in 25% of the patients (sCr 1.5 times from baseline to requiring dialysis), out of which 5% had AKI, which was defined as sCr >3 times baseline. Most of these patients required drug interruption, discontinuation or dose reduction. In another integrated safety profile study of CFZ, there was a 24.1% incidence of an increased sCr, out of which 17.7% were thought to be treatment related. It was interesting to note that, in this

Received: December 1, 2014. Accepted: June 18, 2015

© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

For commercial re-use, please contact journals.permissions@oup.com
study, fever, anemia and thrombocytopenia were also reported in 30, 46 and 29% of patients, respectively.

In the past few years, there have also been a few case reports that have highlighted the association between proteasome inhibitors (BTZ and CFZ) with AKI [17–24]. In most of these case reports and initial trials, underlying mechanism of AKI has been unclear. Vasoconstriction of renal arteries leading to AKI has been hypothesized by Wanchoo et al., and the use of N-acetyl-L-cysteine partially mitigated the renal injury upon re-challenge of CFZ [17].

### Thrombotic microangiopathy associated with proteasome inhibitors

There have been four cases of BTZ-associated AKI with evidence of underlying TMA (Table 1). Kidney biopsy was not performed in any of these cases. Hobeika et al. [20] recently published a case of a patient presenting with worsening hypertension and proteinuria after CFZ exposure. Kidney biopsy showed features of TMA and associated podocytopathy, with foot process effacement. This presentation was not associated with microangiopathic hemolytic anemia (MAHA). A similar pathology has also been described in TMA associated with vascular endothelial growth factor (VEGF) inhibitor exposure [25, 26]. We report the first case of CFZ-associated AKI with kidney biopsy evidence of TMA and the presence of MAHA.

Case Report: A 63-year-old Caucasian male with MM IgG kappa, ISS stage II, status post 2 autologous bone marrow transplants (last one ~6 months prior to this presentation) was found to have AKI (sCr of 6.3 mg/dL (557 µmol/L)) during his routine visit to receive his second dose of CFZ. Two weeks prior to this presentation, he was started on chemotherapy with CFZ. His sCr was 0.7 mg/dL (53 µmol/L) at this time with no evidence of proteinuria. His past medical history was also significant for hypertension, dyslipidemia and urate nephrolithiasis. He was initially diagnosed with MM ~18 months previously when he had presented with a right pleural-based mass, which was associated with a destructive lesion of an adjacent rib. An fine needle aspiration of the lesion was performed at that time, which showed sheets of plasma cells consistent with MM. His kappa-to-lambda ratio (κ/λ) one year previously was 75.84 and was 1.58 at the time of this presentation.

During his current presentation, he reported worsening lower extremity swelling and weight gain with decreasing urine output. He denied having diarrhea, shortness of breath, chest discomfort, orthostatic symptoms or any exposure to any nephrotoxins including contrast agents. His current medications included acyclovir, dexamethasone, fluconazole, fludrocortisone, gabapentin, loratadine, omeprazole, pentamidine inhaled, propranolol, simvastatin and trazodone. His temperature was 98.6°F (37°C), blood pressure was 141/80 mm of Hg (no evidence of orthostasis), pulse 94/min and oxygen saturation 97% on room air. Physical exam revealed mild diffuse bilateral wheezing and lower extremity edema up to the knees. His significant laboratory results are shown in Table 2. Antiphospholipid antibodies and anti-neutrophil cytoplasmic antibody serologies were negative. Serum complements (C3 and C4) were within normal range. Urinalysis was significant for 2+blood and 2+proteins without casts or crystals. Urine microscopy was bland. Urine sodium was 33 mEq/L (33 mmol/L), and urine Cr was 97.1 mg/dL (8583 µmol/L) with a urine protein-to-creatinine ratio (UPCR) of 1.5. Renal ultrasound was unremarkable without any evidence of hydronephrosis. A presumptive diagnosis of thrombotic thrombocytopenic purpura / hemolytic-uremic syndrome symptoms was made, and empiric plasmapheresis was started. The patient was not re-challenged with CFZ again.

Plasmapheresis was continued while ADAMTS13 levels were pending. ADAMTS13 results (>50%) were available on Day 10, and thus plasmapheresis was stopped after five sessions. The patient never required dialysis, and over the next week, his sCr started to improve with improving urine output. The patient underwent an ultrasound guided kidney biopsy 1 week after presentation, when platelets were >65 000 mm3. The biopsy revealed glomerulonephritis with mild acute tubular necrosis (Figs. 1A and B). There was no diagnostic evidence of renal involvement by myeloma or paraproteins. His hemoglobin, platelets, lactate dehydrogenase (LDH) and haptoglobin were normal-ized over the next 3 weeks. The patient was treated supportively for the rest of his stay. His sCr continued to improve, and last known value 45 days after the initial presentation was 1.8 mg/dL (159 µmol/L). Workup for atypical HUS (e.g. complement factor H autoantibodies) was not done, though normal complement level and improvement in TMA argue against it.

### Table 1. Case reports of AKI associated with use of proteasome inhibitors [17–24]

| Study/year | Drug used | Age/sex | AKI | TMA | Time to onset of AKI/TMA | Renal biopsy | BMT | Underlying disease |
|------------|-----------|---------|-----|-----|--------------------------|-------------|-----|--------------------|
| Wanchoo et al. [17] | CFZ | 78/M | + | n/a | Day 2 | No | No | MM |
| Shely et al. [18] | CFZ | 55/M | + | n/a | Day 5 | No | No | MM |
| Hobeika et al. [20] | CFZ | 62/M | – | + | Day 42 | Yes | Yes | MM |
| Hjaveri et al. [19] | CFZ | 68/M | + | n/a | Day 9 | No | No | MM |
| Salmenniemi et al. [23] | BTZ | 52/F | + | + | Day 11 at the fifth treatment | No | Yes | MM |
| Mehta et al. [21] | BTZ | 70/F | + | + | Day 2 after ninth dose | No | No | MM |
| Moore et al. [22] | BTZ | 57/F | + | + | Day 2 | No | Yes | MM |
| Morita et al. [24] | BTZ | 54/M | + | + | Day 8 | No | Yes | MM |

M, Male; F, Female; AKI, acute kidney injury; TMA, thrombotic microangiopathy; BMT, bone marrow transplant.

### Table 2. Laboratory values of patient mentioned in the case report

| Labs at presentation | 4 weeks before presentation | 3 weeks after presentation |
|----------------------|-----------------------------|---------------------------|
| Hb (mg/dL)           | 11.3 (113 g/L)              | 5.7 (57 g/L)              |
| Platelets            | 176                         | 35                        |
| SCr (mg/dL)          | 0.7 (62 µmol/L)             | 6.3 (557 µmol/L)          |
| UPCR                 | 0.1                         | 1.5                       |
| LDH (U/L)            | 170 (1.7 µkat/L)            | 777 (7.77 µkat/L)         |
| Haptoglobin          | <10                         | 180 (1.8 µkat/L)          |
| Schistocytes         | 2+                          | 62                        |

Hb, hemoglobin; SCr, serum creatinine; UPCR, urine protein-to-creatinine ratio; LDH, lactate dehydrogenase.
We postulate CFZ as a potential etiology of TMA. Discontinuation of CFZ along with supportive management was associated with renal recovery in our patient. This patient presented with AKI secondary to TMA associated with MAHA (elevated LDH, low haptoglobin, schistocytes on peripheral blood smear) and thrombocytopenia. Although causality is difficult to establish, initiation of drug followed by rapid onset of AKI without any known precipitating factors and recovery after stopping the drug makes it very convincing to postulate that CFZ induced MAHA with TMA in kidney and this resulted in the development of AKI. The patient in this report had no other obvious cause of AKI including volume depletion, tumor lysis syndrome or administration of iodinated contrast medium. Active infection (sepsis) or the presence of disseminated intravascular coagulation was ruled out with negative blood, urine and respiratory cultures along with a normal fibrinogen level (211 mg/dL). He was not exposed to any other therapeutic agents except CFZ, pomalidomide and dexamethasone 2 months before presentation and was in the middle of his second cycle. This patient did have a history of two hematopoietic stem cell transplants (HSCT) 6 and 9 months prior to the presentation. HSCT has been associated with renal TMA and is called transplant-associated thrombotic microangiopathy (TA-TMA) [27–29]. TA-TMA is believed to be caused by direct microvascular toxicity initiated by endothelial injury [30]. The patient in our report was 6 months out of HSCT and had spontaneous recovery after discontinuation of CFZ, and thus, his presentation was unlikely to be TA-TMA.

**Proposed pathogenesis of proteasome inhibitor-associated thrombotic microangiopathy**

 Syndromes of TMA present clinically with anemia, thrombocytopenia and signs of intravascular hemolysis, e.g. high LDH and low haptoglobin. All of the causes and pathological mechanism create a pro-thrombotic state and potentiate formation of micro-thrombi leading to end-organ damage. TMA can be hereditary and acquired [31, 32] (Table 3).

**Table 3. Causes of TMA [33, 34]**

| Hereditary causes | Acquired causes |
|-------------------|-----------------|
| • ADAMTS 13 deficiency | • Antibodies against ADAMTS13 |
| • Loss of function mutation in the gene controlling alternative complement pathway regulatory proteins, e.g. Factor H | • Shiga toxin activatingGb3 |
| • Mutation in MMAHC and DGKE genes | • Antibodies against Factor H |
| | • Drug-induced TMA (VEGF inhibition and/or drug-dependent antibodies) |

VEGF inhibition has been proposed as one of the potential pathological factors responsible for TMA associated with AKI [25, 26]. VEGF is critical in maintenance and growth of normal vasculature. It is produced by podocytes in high concentration against the urinary membrane, and with its concentration gradient to bind to its receptors on glomerular endothelial cells. Podocytes and glomerular endothelial cells use VEGF-VEGF-R2 signaling for transmembrane communication, which is essential for structural and functional integrity of glomerular endothelium and fenestrations [35]. Any disruption of this mechanism by inhibiting its production (proteasome inhibitors), using bevacizumab (anti-VEGF antibodies), pazopanib (inhibits VEGF 1–3) and sunitinib (VEGF tyrosine kinase inhibitor) can potentially lead to kidney damage specifically TMA and podocytopathy causing proteinuria and hypertension [25, 26, 35].

Proteasome inhibitors affect VEGF pathways via NF-κB pathways [33, 34, 36] (Figure 2). NF-κB is a protein involved in the regulation of genetic transcription. NF-κB activation in response to various
extracellular signals (including reactive oxygen species, TNF-α, IL-1β, bacterial polysaccharides and radiation) is initiated by degradation of IκB (inhibitor of NF-κB). IκB kinase (IKK), when activated by extracellular signals described above, causes phosphorylation of IκB leading to ubiquitination of IκB. After IκB degradation, NF-κB is free to enter the nucleus and influence DNA transcription [37]. An increase in the activity of NF-κB promotes VEGF expression [38]. Proteasome inhibitors prevent ubiquitination of IκB even after phosphorylation by IKK; this in turn prevents NF-κB from entering the nucleus and affecting transcription. Thus, proteasome inhibitors decrease NF-κB levels in the nucleus leading to decreased VEGF production [39–41], potentially predisposing to TMA.

Acknowledgements
Danielle G. Holanda, Department of Pathology, University of Iowa Hospitals and Clinics.

Conflicts of interest statement
None declared.

References
1. Tomoda H, Omura S. Lactacystin, a proteasome inhibitor: discovery and its application in cell biology. Yakugaku Zasshi 2000; 120: 935–949
2. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995; 217: 1070–1077
3. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335–348
4. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622
5. Teicher BA, Ara G, Herbst R et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638–2645
6. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
7. Carfilzomib. NCI Drug Directory. http://www.cancer.gov/drugdictionary/?CdrID=459751
8. FDA approves Kyprolis for some patients with multiple myeloma. 2012 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312920.htm (20 July 2012, date last accessed)
9. Demo SD, Kirk CJ, Aujay MA et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383–6391
10. Pautasso C, Brighen S, Cerrato C et al. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 2013; 9: 1371–1379
11. Arasu-Kapur S, Anderlj JL, Kraus M et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011; 17: 2734–2743
12. Jagannath S, Barlogie B, Berenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
13. Ludwig H, Khayat D, Giaccone G et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005; 104: 1794–1807
14. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
15. Siegel DS, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753–1761
16. Siegel DS, Martin T, Wang M et al. A phase 2 study of single-agent carfilzomib (PX-171–003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817–2825
17. Wanchoo R, Khan S, Kolitz JE et al. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. J Oncol Pharm Pract 2015; 21: 313–316
18. Shely RN, Ratilff PD. Carfilzomib-associated tumor lysis syndrome. Pharmacotherapy 2014; 34: e34–e37
19. Jhaiveri KD, Chidella S, Varghese J et al. Carfilzomib-related acute kidney injury. Clin Adv Hematol Oncol 2013; 11: 604–605
20. Hobeika L, Self SE, Velez JC. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 2014; 15: 156
21. Mehta N, Saxena A, Niesvizky R. Bortezomib-induced thrombotic thrombocytopenic purpura. BMJ Case Rep 2012; doi: 10.1136/bcr-2012-006461
22. Moore H, Romeril K. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J 2011; 41: 348–350
23. Salmenniemi U, Remes K. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 2012; 4: e13
24. Morita R, Hashino S, Shirai S. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 2008; 88: 248–250
25. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–1136
26. Eremina V, Quaggin SE. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol 2010; 30: 582–590
27. Roy V, Rizvi MA, Vesely SK et al. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27: 641–646
28. Siami K, Kojouri K, Swisher KK et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008; 85: 22–28
29. Ho VT, Cutler C, Carter S et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575
30. Ruutu T, Barosi G, Benjamin RJ et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100
31. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 654–666
32. Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? ASH Educ Program Book 2012; 2012: 617–625
33. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade-trade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag 2006; 2: 271–279
34. Salem K, Brown CO, Schibler J et al. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-kappaB activity. Exp Hematol 2013; 41: 209–218
35. Usui J, Glezerman IG, Salvatore SP et al. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol 2014; 45: 1918–1927
36. Kiriakidis S, Andreakos E, Monaco C et al. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003; 116: 665–674
37. Nelson DE, Ihekwaba AE, Elliott M et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004; 306: 704–708
38. Zhang J, Peng B. NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. Cell Prolif 2009; 42: 150–161
39. Greenberger S, Adini I, Boscolo E et al. Targeting NF-kappaB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010; 13: 327–335
40. Shibata A, Nagaya T, Imai T et al. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002; 73: 237–243
41. Thapa RJ, Chen P, Cheung M et al. NF-kappaB inhibition by bortezomib permits IFN-gamma-activated RIP1 kinase-dependent necrosis in renal cell carcinoma. Mol Cancer Ther 2013; 12: 1568–1578